Search - tctmd.com

Displaying 81 - 100 of 108

Presentation TCT 2012

Glycoprotein IIb/IIIa Inhibitors in the Era of Bivalirudin and New Oral Antiplatelet Agents: Is Intracoronary Application the Standard of Choice?

Presenter: Rajesh Dave

October 25, 2012

$Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!$

Presentation TCT 2012

Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!

Presenter: Gilles Montalescot

October 25, 2012

News Daily News

Bivalirudin Lowers Bleeding in NSTEMI Patients Undergoing PCI

Jason Kahn

October 19, 2012

News Daily News

Guidelines Elevate Ticagrelor to First-line Antiplatelet Status in Unstable Angina

Jason Kahn

July 17, 2012

News Daily News

HORIZONS-AMI: Similar Outcomes with Abciximab, Eptifibatide During Primary PCI

July 05, 2012

News Daily News

Meta-analysis Favors Intracoronary vs. Intravenous Abciximab in Primary PCI

June 05, 2012

News Conference News ACC 2012

INFUSE-AMI: Bolus Abciximab Works, Thrombus Aspiration Doesn’t for Large STEMI

Jason Kahn

March 25, 2012

News Daily News

Registry Confirms Bivalirudin Better for STEMI in ‘Real World’

March 07, 2012

News Daily News

MISTRAL: No Lasting Benefit from Early Abciximab in STEMI Patients

Caitlin E. Cox

February 09, 2012

News Conference News

AIDA STEMI: No Advantage for Intracoronary vs. Intravenous Abciximab

November 13, 2011

News Daily News

Meta-analysis: Intracoronary vs. IV Abciximab Improves Survival in STEMI Patients

L.A. McKeown

November 01, 2011

News Daily News

Bivalirudin Decreases Bleeding Regardless of Heparin Anticoagulation Level

Yael L. Maxwell

October 13, 2011

News Daily News

HORIZONS-AMI: CKD Patients Fare Poorly Regardless of Stent Type, Antithrombotic Regimen

Leah Lawrence

September 29, 2011

News Daily News

STEMI Patients Benefit From Clopidogrel Given Prior to PCI Center

Caitlin E. Cox

September 28, 2011

News Daily News

HORIZONS-AMI: Bivalirudin Reduces Cardiac Death in Diabetics

Jason Kahn

July 18, 2011

News Daily News

Meta-analysis: Selective Use of Small-Molecule GPIs Best in NSTE ACS Patients

Caitlin E. Cox

July 08, 2011

News Daily News

BARC: New Bleeding Definitions Aim to Standardize Trial Endpoints

L.A. McKeown

June 17, 2011

News Daily News

One-Month Platelet Reactivity After PCI Key Risk Factor for Future Events

June 13, 2011

News Daily News

HORIZONS-AMI Published: Bivalirudin, Taxus Stay Strong at 3 Years

Jason Kahn

June 13, 2011

News Daily News

Predictors of Serious Bleeding in ACS Patients from TRITON-TIMI Identified

June 09, 2011

Advertisement

Glycoprotein IIb/IIIa Inhibitors in the Era of Bivalirudin and New Oral Antiplatelet Agents: Is Intracoronary Application the Standard of Choice?

Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!

Bivalirudin Lowers Bleeding in NSTEMI Patients Undergoing PCI

Guidelines Elevate Ticagrelor to First-line Antiplatelet Status in Unstable Angina

HORIZONS-AMI: Similar Outcomes with Abciximab, Eptifibatide During Primary PCI

Meta-analysis Favors Intracoronary vs. Intravenous Abciximab in Primary PCI

INFUSE-AMI: Bolus Abciximab Works, Thrombus Aspiration Doesn’t for Large STEMI

Registry Confirms Bivalirudin Better for STEMI in ‘Real World’

MISTRAL: No Lasting Benefit from Early Abciximab in STEMI Patients

AIDA STEMI: No Advantage for Intracoronary vs. Intravenous Abciximab

Meta-analysis: Intracoronary vs. IV Abciximab Improves Survival in STEMI Patients

Bivalirudin Decreases Bleeding Regardless of Heparin Anticoagulation Level

HORIZONS-AMI: CKD Patients Fare Poorly Regardless of Stent Type, Antithrombotic Regimen

STEMI Patients Benefit From Clopidogrel Given Prior to PCI Center

HORIZONS-AMI: Bivalirudin Reduces Cardiac Death in Diabetics

Meta-analysis: Selective Use of Small-Molecule GPIs Best in NSTE ACS Patients

BARC: New Bleeding Definitions Aim to Standardize Trial Endpoints

One-Month Platelet Reactivity After PCI Key Risk Factor for Future Events

HORIZONS-AMI Published: Bivalirudin, Taxus Stay Strong at 3 Years

Predictors of Serious Bleeding in ACS Patients from TRITON-TIMI Identified

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content